Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - Deferred ChargesCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Issued
Ratios

Celularity (CELU) EBIAT (2020 - 2025)

Celularity has reported EBIAT over the past 6 years, most recently at -$23.1 million for Q3 2025.

  • Quarterly results put EBIAT at -$23.1 million for Q3 2025, down 100.19% from a year ago — trailing twelve months through Sep 2025 was -$96.2 million (down 215.5% YoY), and the annual figure for FY2024 was -$57.9 million, up 70.51%.
  • EBIAT for Q3 2025 was -$23.1 million at Celularity, up from -$24.5 million in the prior quarter.
  • Over the last five years, EBIAT for CELU hit a ceiling of $57.3 million in Q4 2022 and a floor of -$93.9 million in Q3 2023.
  • Median EBIAT over the past 5 years was -$22.0 million (2024), compared with a mean of -$18.8 million.
  • Biggest five-year swings in EBIAT: skyrocketed 1517.75% in 2022 and later crashed 2056.16% in 2023.
  • Celularity's EBIAT stood at -$4.0 million in 2021, then skyrocketed by 1517.75% to $57.3 million in 2022, then tumbled by 83.33% to $9.5 million in 2023, then plummeted by 401.81% to -$28.8 million in 2024, then grew by 19.91% to -$23.1 million in 2025.
  • The last three reported values for EBIAT were -$23.1 million (Q3 2025), -$24.5 million (Q2 2025), and -$19.8 million (Q1 2025) per Business Quant data.